What potential therapy reports out next? There are not a lot of large, late stage, Alzheimer’s trial results expected until 2019 (including Biogen’s aducanumab, Merck’s BACE- oriented verubecestat, and Lilly/AstraZeneca’s lanabecestat).
“Our results demonstrate that ApoE affects tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-β pathology. ApoE4 exerts a ‘toxic’ gain of function whereas the absence of ApoE is protective” David Holtzman, MD Washington University
Dr Sadowski talks about the potential of the EXERT Study to help identify the right dose of exercise to offset memory loss for people at risk for Alzheimer’s disease
The Biohaven Pharmaceutical Holding Company Ltd. announced today its clinical trial collaboration with the Alzheimer’s Disease Cooperative Study (ADCS).
A family with an astonishing rate of Alzheimer’s disease may harbor a powerful new gene.